Ovarian cancer development and metastasis.

The American Journal of Pathology
Ernst Lengyel

Abstract

The biology of ovarian carcinoma differs from that of hematogenously metastasizing tumors because ovarian cancer cells primarily disseminate within the peritoneal cavity and are only superficially invasive. However, since the rapidly proliferating tumors compress visceral organs and are only temporarily chemosensitive, ovarian carcinoma is a deadly disease, with a cure rate of only 30%. There are a number of genetic and epigenetic changes that lead to ovarian carcinoma cell transformation. Ovarian carcinoma could originate from any of three potential sites: the surfaces of the ovary, the fallopian tube, or the mesothelium-lined peritoneal cavity. Ovarian cacinoma tumorigenesis then either progresses along a stepwise mutation process from a slow growing borderline tumor to a well-differentiated carcinoma (type I) or involves a genetically unstable high-grade serous carcinoma that metastasizes rapidly (type II). During initial tumorigenesis, ovarian carcinoma cells undergo an epithelial-to-mesenchymal transition, which involves a change in cadherin and integrin expression and up-regulation of proteolytic pathways. Carried by the peritoneal fluid, cancer cell spheroids overcome anoikis and attach preferentially on the abdominal pe...Continue Reading

References

Oct 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·J Q ChengJ R Testa
Nov 1, 1972·Obstetrical & Gynecological Survey·M F Fathalla
Aug 1, 1994·International Journal of Cancer. Journal International Du Cancer·A L VeatchS Ramakrishnan
Sep 15, 1993·Journal of the National Cancer Institute·M F KohlerA Berchuck
Sep 4, 1996·International Journal of Cancer. Journal International Du Cancer·T L MoserM S Stack
Oct 18, 1996·Cell·K W Kinzler, B Vogelstein
Jan 23, 1999·Nature Genetics·L ShayestehJ W Gray
Oct 26, 2001·Journal of the Society for Gynecologic Investigation·C A WitzR S Schenken
Dec 6, 2001·The American Journal of Pathology·R C CaseyA P Skubitz
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert E BristowF J Montz
Aug 8, 2002·Journal of the National Cancer Institute·Suyun HuangIsaiah J Fidler
Dec 7, 2002·Nature Genetics·Sridhar RamaswamyTodd R Golub
Mar 20, 2003·Journal of the National Cancer Institute·Gad SingerIe-Ming Shih
Jun 12, 2003·International Journal of Cancer. Journal International Du Cancer·Ila S PatelColin D MacCalman
Jul 10, 2003·The Lancet Oncology·Alain G Zeimet, Christian Marth
Sep 26, 2003·The American Journal of Pathology·Tsutomu ImaiIkuo Konishi
Oct 3, 2003·Journal of the American College of Surgeons·Robert E BristowFredrick J Montz
Feb 18, 2004·Nature Reviews. Cancer·Ugo Cavallaro, Gerhard Christofori
Jul 28, 2004·The American Journal of Pathology·Kathleen HibbsAmy P N Skubitz
Sep 24, 2004·Cancer Genetics and Cytogenetics·Ofir IsraeliAyala Aviram-Goldring
Oct 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chih-Yi HsuIe-Ming Shih
Dec 14, 2004·The New England Journal of Medicine·Stephen A Cannistra
Dec 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C Bethan PowellJohn Ziegler
Jul 23, 2005·Clinical & Experimental Metastasis·Kathryn M BurlesonAmy P N Skubitz
Aug 16, 2005·Current Opinion in Cell Biology·Margit A HuberHartmut Beug
Sep 8, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca T MarquezKaren H Lu
Oct 6, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Limin HuRobert B Jaffe
Mar 1, 2006·International Journal of Cancer. Journal International Du Cancer·Amanda H ProwseStephen H Kennedy
Jul 20, 2006·Proceedings of the National Academy of Sciences of the United States of America·Paul P SzotekPatricia K Donahoe
Aug 2, 2006·Obstetrics and Gynecology·David M GershensonDiane C Bodurka
Nov 18, 2006·Cell·Gaorav P Gupta, Joan Massagué
Jan 27, 2007·The American Journal of Surgical Pathology·David W KindelbergerChristopher P Crum

❮ Previous
Next ❯

Citations

Apr 18, 2013·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Yu-Mei RaoHui-Rong Shi
Mar 8, 2013·Nature·Andrea Flesken-NikitinAlexander Yu Nikitin
Nov 1, 2011·Nature Medicine·Kristin M NiemanErnst Lengyel
May 7, 2013·Proceedings of the National Academy of Sciences of the United States of America·Imran RizviTayyaba Hasan
Mar 23, 2013·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Lars Christian HankerKnut Engels
Jan 12, 2012·Journal of Oncology·Kenjiro SawadaKen-Ichirou Morishige
Jan 16, 2013·Pathology Research International·Paulette Mhawech-FaucegliaTanja Pejovic
Dec 15, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hilary A KennyErnst Lengyel
May 10, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marion ZillhardtErnst Lengyel
Oct 18, 2012·Molecular Cancer Therapeutics·Diana M CittellyJennifer K Richer
Feb 9, 2012·Onkologie·Nina Ewald-RieglerAndreas du Bois
Sep 5, 2012·The Journal of Clinical Investigation·Song Yi KoHonami Naora
May 31, 2012·BMC Cancer·Carlos D Gamarra-LuquesCarlos M Telleria
Apr 5, 2013·PloS One·Souriya VangAlexander S Brodsky
Mar 4, 2014·PloS One·Eoghainín Ó hAinmhireJoanna E Burdette
Jan 5, 2014·International Journal of Molecular Sciences·Goda G Muralidhar, Maria V Barbolina
Jun 13, 2014·PloS One·Yin-Ling XiuHua-Chuan Zheng
Feb 28, 2014·Proceedings of the National Academy of Sciences of the United States of America·Bryan Q SpringTayyaba Hasan
Jul 9, 2011·EMBO Molecular Medicine·Silvia ZecchiniUgo Cavallaro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cachexia & Brown Fat

Cachexia is a condition associated with progressive weight loss due to severe illness. In cancer patients, it is proposed to occur as a result of tumor-induced energy wasting. Several proteins have been implicated in browning and depletion of white adipose tissue. Here is the latest research on cachexia and brown fat.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Basement Membranes

Basement membranes are thin, specialized extracellular matrices surrounding most tissues in all metazoans. Here is the latest research on basement membranes.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.

Cadherins and Catenins

Cadherins (named for "calcium-dependent adhesion") are a type of cell adhesion molecule (CAM) that is important in the formation of adherens junctions to bind cells with each other. Catenins are a family of proteins found in complexes with cadherin cell adhesion molecules of animal cells: alpha-catenin can bind to β-catenin and can also bind actin. β-catenin binds the cytoplasmic domain of some cadherins. Discover the latest research on cadherins and catenins here.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Adherens Junctions

An adherens junction is defined as a cell junction whose cytoplasmic face is linked to the actin cytoskeleton. They can appear as bands encircling the cell (zonula adherens) or as spots of attachment to the extracellular matrix (adhesion plaques). Adherens junctions uniquely disassemble in uterine epithelial cells to allow the blastocyst to penetrate between epithelial cells. Discover the latest research on adherens junctions here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.